{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Colorectal Neoplasms","Colorectal Cancer Metastatic"],"disease":["Colorectal Neoplasms","Colorectal Cancer Metastatic"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2130809"],"location":["France"],"study_start_month":["8"],"keyword":["Irinotecan","Leucovorin","Aflibercept","Fluorouracil"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Colorectal Cancer Metastatic","description":"Primary Objective:\nTo evaluate the safety of aflibercept in participants with mCRC treated with irinotecan/5-Fluorouracil (5-FU) combination (FOLFIRI) after failure of an oxaliplatin-based regimen (participants similar to those evaluated in the VELOUR trial [EFC10262, NCT00561470]) according to side effects prevention and management guidelines.\nSecondary Objective:\nTo document the Health-Related Quality of Life (HRQL) of aflibercept in this participant population.","dates":{"creation":"2012-08-15"},"accession":"2130809","cross_references":{"ClinicalTrials___gov":["NCT01670721"],"International Clinical Trials Registry Platform":["U1111-1128-9325"],"EU Clinical Trials Register":["2012-000048-89"]}}